Ignite Creation Date:
2024-05-06 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05265910
Status:
COMPLETED
Last Update Posted:
2022-05-03
First Post:
2021-12-14
Brief Title:
A Study Comparing the Efficacy of Pataday Once Daily Relief Extra Strength to Claritin Tablets 24-Hour in Subjects With Allergic Conjunctivitis
Sponsor:
Andover Research Eye Institute
Organization:
Andover Research Eye Institute
Study Overview
Official Title:
A Single-Center Randomized Double-Masked Parallel Study Comparing the Efficacy of Pataday Once Daily Relief Extra Strength to Claritin Tablets 24-Hour in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis
Status:
COMPLETED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-center randomized double-masked parallel study In this clinical study the efficacy comparison between Pataday Once Daily Relief Extra Strength and Claritin Tablets 24-Hour will be made using the Ora-CAC model a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None